Trial reportHereditas2025
Impact of early blood purification on serum inflammatory mediators and hemorheology in severe acute pancreatitis.
Trial report in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hemoperfusion with Hemodiafiltration Versus Standard Medical Therapy for Severe Acute Pancreatitis: A Retrospective Study.Digestive diseases and sciences · 2026Article
- A Novel Triple-Biomarker Score Predicts Mortality in Acute Pancreatitis.Gastroenterology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with severe acute pancreatitis (SAP) often experience systemic inflammatory responses and microcirculatory disturbances, for which existing treatments have limited intervention effects.
objectivesIt aimed to investigate the impact of early blood purification on serum inflammatory mediators, hemorheological parameters, and clinical prognosis in patients with SAP.
methods120 patients with SAP were randomly grouped: observation group (OG) (routine treatment + early continuous veno-venous hemodiafiltration) and control group (CG) (routine treatment). The time to clinical symptom improvement, hemorheological parameters [whole blood viscosity (WBV), plasma viscosity (PV), hematocrit, and platelet adhesion rate], and inflammatory mediators were compared. Multivariate logistic regression analysis (MLRA) was used to identify prognostic factors.
resultsThe OG had markedly shorter times to symptom relief for fever, abdominal pain, and abdominal distension (all P < 0.001) and a higher cure rate (P = 0.012); The levels of C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), as well as WBV and PV, were more markedly improved (all P < 0.01). Multivariate analysis suggested that peak CRP (OR = 1.01, P < 0.001) and peak TNF-α (OR = 1.02, P = 0.003) maintained independent predictive value, and all hemorheological parameters were confirmed as independent prognostic factors.
conclusionEarly blood purification can effectively improve the inflammatory response and hemodynamics in patients with SAP, with its efficacy influenced by multiple factors, including disease severity, intensity of inflammatory response, and hemorheological status. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.